Results 231 to 240 of about 29,053 (244)
Some of the next articles are maybe not open access.
Introduction to Radionuclide Therapy
2008This introductory chapter is written for those who are new to the field and desire a short overview of the present status of clinical and preclinical radionuclide therapy. In particular, this chapter provides an overview of the radiophysical concepts and key aspects of dosimetry and treatment planning that are beyond the scope of this book’s focus on ...
Jörgen Carlsson +2 more
openaire +2 more sources
2016
Therapeutic applications of alpha (α)-emitting radionuclides were introduced soon after the isolation of radium from pitch blende by Marie Curie in the early twentieth century. Because of the very high linear energy transfer (LET), α-emitters can be very lethal and result in very effective cell killing sterilization if the α-decay commences at the ...
Ashutosh Dash, Furn F. Knapp
openaire +2 more sources
Therapeutic applications of alpha (α)-emitting radionuclides were introduced soon after the isolation of radium from pitch blende by Marie Curie in the early twentieth century. Because of the very high linear energy transfer (LET), α-emitters can be very lethal and result in very effective cell killing sterilization if the α-decay commences at the ...
Ashutosh Dash, Furn F. Knapp
openaire +2 more sources
Peptides for Radionuclide Therapy
2008Somatostatin receptor-targeting peptides are widely being used for imaging and therapy of neuroendocrine tumors. Peptide receptor radionuclide therapy (PRRT) with e.g. 177Lu labeled somatostatin analogues in neuroendocrine tumor patients has resulted in symptomatic improvement, prolonged survival and enhanced quality of life.
Roelf Valkema +5 more
openaire +2 more sources
Bone-Seeking Radionuclide for Therapy
2016Ionising radiation is utilised in a variety of situations in the management of prostate cancer. Beyond the scope of this book is the use of brachytherapy and external beam radiotherapy (EBRT) as efficacious, radical treatment modalities in the management of localised prostate cancer. Earlier chapters have covered the use of EBRT as a therapeutic option
O’Sullivan, Joe, Turner, Phil
openaire +3 more sources
Targeted Radionuclide Therapy in Glioblastoma
ACS Applied Materials & InterfacesDespite the development of various novel therapies, glioblastoma (GBM) remains a devastating disease, with a median survival of less than 15 months. Recently, targeted radionuclide therapy has shown significant progress in treating solid tumors, with the approval of Lutathera for neuroendocrine tumors and Pluvicto for prostate cancer by the US Food and
Xiaobin Zhao +7 more
openaire +2 more sources
Bystander Effects and Radionuclide Therapy
2008The standard paradigm for radiation effects in biological systems is that direct DNA damage within the nucleus of a cell is required to trigger the down-stream biological consequences. However, significant evidence has been obtained for the presence of bystander effects where cells respond to the fact that their neighbours have been irradiated. As well
openaire +2 more sources
Future of radionuclide therapy
International Congress Series, 2002M Fischer, W Becker
openaire +2 more sources